563 related articles for article (PubMed ID: 26613768)
1. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
[TBL] [Abstract][Full Text] [Related]
2. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.
McInnes IB; Thompson L; Giles JT; Bathon JM; Salmon JE; Beaulieu AD; Codding CE; Carlson TH; Delles C; Lee JS; Sattar N
Ann Rheum Dis; 2015 Apr; 74(4):694-702. PubMed ID: 24368514
[TBL] [Abstract][Full Text] [Related]
3. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.
Strang AC; Bisoendial RJ; Kootte RS; Schulte DM; Dallinga-Thie GM; Levels JH; Kok M; Vos K; Tas SW; Tietge UJ; Müller N; Laudes M; Gerlag DM; Stroes ES; Tak PP
Atherosclerosis; 2013 Jul; 229(1):174-81. PubMed ID: 23746537
[TBL] [Abstract][Full Text] [Related]
4. Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial.
Mašić D; Stengaard-Pedersen K; Løgstrup BB; Hørslev-Petersen K; Hetland ML; Junker P; Østergaard M; Ammitzbøll C; Möller S; Christensen R; Ellingsen T
Rheumatol Int; 2021 Mar; 41(3):543-549. PubMed ID: 33386898
[TBL] [Abstract][Full Text] [Related]
5. Remodeling of plasma lipoproteins in patients with rheumatoid arthritis: Interleukin-6 receptor-alpha inhibition with tocilizumab.
Lee JS; Chapman MJ; Piraino P; Lamerz J; Schindler T; Cutler P; Dernick G
Proteomics Clin Appl; 2016 Feb; 10(2):183-94. PubMed ID: 26201085
[TBL] [Abstract][Full Text] [Related]
6. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.
Park YB; Choi HK; Kim MY; Lee WK; Song J; Kim DK; Lee SK
Am J Med; 2002 Aug; 113(3):188-93. PubMed ID: 12208376
[TBL] [Abstract][Full Text] [Related]
7. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.
Ormseth MJ; Yancey PG; Solus JF; Bridges SL; Curtis JR; Linton MF; Fazio S; Davies SS; Roberts LJ; Vickers KC; Kon V; Michael Stein C;
Arthritis Rheumatol; 2016 Sep; 68(9):2099-105. PubMed ID: 26991245
[TBL] [Abstract][Full Text] [Related]
8. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
[TBL] [Abstract][Full Text] [Related]
9. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
[TBL] [Abstract][Full Text] [Related]
10. High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study.
Jamnitski A; Levels JH; van den Oever IA; Nurmohamed MT
J Rheumatol; 2013 Jun; 40(6):825-30. PubMed ID: 23637327
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
Gabay C; Emery P; van Vollenhoven R; Dikranian A; Alten R; Pavelka K; Klearman M; Musselman D; Agarwal S; Green J; Kavanaugh A;
Lancet; 2013 May; 381(9877):1541-50. PubMed ID: 23515142
[TBL] [Abstract][Full Text] [Related]
12. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
[TBL] [Abstract][Full Text] [Related]
13. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation.
Dursunoğlu D; Evrengül H; Polat B; Tanriverdi H; Cobankara V; Kaftan A; Kiliç M
Rheumatol Int; 2005 May; 25(4):241-5. PubMed ID: 15290086
[TBL] [Abstract][Full Text] [Related]
14. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.
Liao KP; Playford MP; Frits M; Coblyn JS; Iannaccone C; Weinblatt ME; Shadick NS; Mehta NN
J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637346
[TBL] [Abstract][Full Text] [Related]
15. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.
Charles-Schoeman C; Gugiu GB; Ge H; Shahbazian A; Lee YY; Wang X; Furst DE; Ranganath VK; Maldonado M; Lee T; Reddy ST
Atherosclerosis; 2018 Aug; 275():107-114. PubMed ID: 29886354
[TBL] [Abstract][Full Text] [Related]
16. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
Naerr GW; Rein P; Saely CH; Drexel H
Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
[TBL] [Abstract][Full Text] [Related]
17. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.
Wijbrandts CA; van Leuven SI; Boom HD; Gerlag DM; Stroes EG; Kastelein JJ; Tak PP
Ann Rheum Dis; 2009 Aug; 68(8):1316-21. PubMed ID: 18723565
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis.
Robertson J; Porter D; Sattar N; Packard CJ; Caslake M; McInnes I; McCarey D
Ann Rheum Dis; 2017 Nov; 76(11):1949-1952. PubMed ID: 28916714
[TBL] [Abstract][Full Text] [Related]
19. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.
Souto A; Salgado E; Maneiro JR; Mera A; Carmona L; Gómez-Reino JJ
Arthritis Rheumatol; 2015 Jan; 67(1):117-27. PubMed ID: 25303044
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile.
Hurt-Camejo E; Paredes S; Masana L; Camejo G; Sartipy P; Rosengren B; Pedreno J; Vallve JC; Benito P; Wiklund O
Arthritis Rheum; 2001 Dec; 44(12):2761-7. PubMed ID: 11762936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
